Summit Therapeutics Inc
SMMTLatest QuantConomy context for SMMT: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicinal therapies. The company is primarily engaged in the development of antibiotic medicines and oncology treatments. Its lead development candidate, ivonescimab, is a bispecific antibody that combines immunotherapy through PD-1 blockade with anti-angiogenesis effects by blocking VEGF, and is currently in Phase III clinical trials for non-small cell lung cancer (NSCLC) and other solid tumors. Additionally, Summit has a portfolio of anti-infectives, including SMT-738, a novel class of precision antibiotics for treating multidrug-resistant infections. The company operates in the United States and the United Kingdom and has strategic collaborations with entities such as Akeso, Inc. and The University of Texas MD Anderson Cancer Center to accelerate its drug development programs.
- Symbol
- SMMT
- Name
- Summit Therapeutics Inc
- Coverage
- 3 market/data records
- Sources
- alphavantage alpaca fmp sec nasdaq
Recent signals for SMMT
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| earnings release | neutral | 40 | Jan 12, 12:00 AM | SMMT filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-01-12. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read). |
| earnings release | neutral | 40 | Feb 23, 12:00 AM | SMMT filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-02-23. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read). |
| uptrend | very bullish | 100 | Jun 22, 07:14 PM | SMMT uptrend (gain): price 7.38% (strength 100, current 14.185) |
EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).
PRICE signals are experimental: realized 30-day directional accuracy is ~18% (short-horizon price moves tend to mean-revert). They are automatically down-weighted in composite scores but served raw here. Do not use them as standalone trade advice.
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| SMMT | NASDAQ | alphavantage | Summit Therapeutics Inc |
| SMMT | NASDAQ | alpaca | Summit Therapeutics Inc. Common Stock |
| SMMT | NASDAQ | fmp | Summit Therapeutics Inc. |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Zanganeh Mahkam | Co-Chief Executive Officer | purchase | 3,810,000 | $13.12 | $49,987,200 | 4 on EDGAR |
| Jun 12, 2026 | DUGGAN ROBERT W | Co-Chief Executive Officer | purchase | 3,810,000 | $13.12 | $49,987,200 | 4 on EDGAR |
| Jun 4, 2026 | Zanganeh Mahkam | Co-Chief Executive Officer | purchase | 100,000 | $14.60 | $1,460,000 | 4 on EDGAR |
| Jun 4, 2026 | DUGGAN ROBERT W | Co-Chief Executive Officer | purchase | 100,000 | $14.60 | $1,460,000 | 4 on EDGAR |
| Jun 4, 2026 | Soni Manmeet Singh | COO and CFO | purchase | 25,000 | $14.46 | $361,500 | 4 on EDGAR |
| Jan 8, 2026 | Anand Bhaskar | Chief Accounting Officer | grant | 30,000 | — | — | 4 on EDGAR |
| Jan 2, 2026 | Cesano Alessandra | Insider | grant | 35,000 | — | — | 4 on EDGAR |
| Jan 2, 2026 | Clark Kenneth A | Insider | grant | 35,000 | — | — | 4 on EDGAR |
| Jan 2, 2026 | DUGGAN ROBERT W | Co-Chief Executive Officer | grant | 11,232 | $8.76 | $98,392 | 4 on EDGAR |
| Jan 2, 2026 | Zanganeh Mahkam | Co-Chief Executive Officer | grant | 11,232 | $8.76 | $98,392 | 4 on EDGAR |
| Jan 2, 2026 | Ronaghi Mostafa | Insider | grant | 35,000 | — | — | 4 on EDGAR |
| Jan 2, 2026 | Huber Jeff | Insider | grant | 35,000 | — | — | 4 on EDGAR |
| Jan 2, 2026 | Booth Robert F. | Insider | grant | 35,000 | — | — | 4 on EDGAR |
| Jan 2, 2026 | Xia Yu | Insider | grant | 35,000 | — | — | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query SMMT context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access